Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017


January 23, 2018 OrthoSpineNews

January 23, 2018

HUNTLEY, Ill.–(BUSINESS WIRE)–Centric Medical, a division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology announced today the FDA 510(k) clearance of the new Foot and Ankle Plating System. This clearance offers multiple surgical solutions by Centric Medical, to be used in Foot & Ankle reconstruction procedures.

The Centric Medical Foot and Ankle Plating System is comprised of a variety of plates and screws intended to stabilize and fixate bone for a myriad of procedures. The low-profile plates and self-drilling and self-tapping screws were designed to minimize soft tissue disruption and irritation. They are offered in non-sterile, single use implantable components and are provided in a multitude of sizes and shapes which include plates specifically designed for metatarsal phalangeal fusions, lapidus fusions, midfoot fusions and calcaneal slide osteotomies.

“The new Centric Medical Foot and Ankle Plating System is an integral and essential system which adds to a portfolio previously comprised of novel technologies. When paired with our recently FDA cleared Cannulated Screw Internal Fixation System, and our existing OSTEO-LINK® DBM biologics product, we have the potential for excellent clinical outcomes,” said Mariusz Knap, Vice President of Marketing for Life Spine. “As one of the fastest-growing, most innovative companies in our space it is crucial to our surgeons and patients that we continue to advance our offerings.”

About Centric Medical

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Centric Medical, which is privately held, is based in Huntley, Illinois. For more information, please visit:


For Centric Medical
Mr. Omar Faruqi
Chief Financial Officer


January 23, 2018 OrthoSpineNews

SHELTON, Conn., Jan. 23, 2018 (GLOBE NEWSWIRE) — Spine Wave is pleased to announce its commercial launch of the GraftMag® Graft Delivery System.  The GraftMag® Graft Delivery System is designed to safely and rapidly deliver large amounts of bone graft.  The system can transform the tedious and sometimes frustrating graft delivery process into a more efficient part of thoracolumbar spinal fusion surgeries and, due to less instrument passes by sensitive patient anatomy, may reduce the risk of injury.

The GraftMag® Graft Delivery System is comprised of two single use, 5cc graft magazines that are loaded with bone graft on the back table.  The magazines couple with the system’s specially-designed funnels to rapidly deliver large amounts of graft in 1cc increments.  This new grafting approach can reduce frustrating funnel jams and requires only one instrument pass into the graft site to complete the grafting procedure.  The GraftMag® Graft Delivery System can be used in virtually any thoracolumbar spine fusion procedure and with any interbody device.  However, it fits particularly well with Spine Wave’s exciting line of expandable interbody fusion products, especially the Leva® Interbody Devices, which are well known for uniquely accommodating large amounts of bone graft with their use.

“Clinical research indicates that fusion rates are positively correlated with the amount of implanted graft material.  I developed the GraftMag® Graft Delivery System with Spine Wave to make delivering large amounts of graft material faster, easier, safer, and less costly when used in conjunction with any interbody device,” said Dennis Crandall, M.D., Medical Director of Sonoran Spine in Tempe Arizona, and Chairman of the Sonoran Spine Research and Education Foundation.  “Using the GraftMag® Graft Delivery System in conjunction with Spine Wave’s line of Leva® Interbody Devices is a particularly compelling option for many of my thoracolumbar spinal fusion procedures because those devices can accommodate so much graft.”

About Spine Wave
Spine Wave is a leader in expandable fusion technologies and is committed to continually delivering highly differentiated products to enable more efficient and less invasive solutions for spine surgeons and their patients. In addition to the GraftMag® Graft Delivery System, Spine Wave also offers a broad portfolio of expandable devices marketed under the StaXx®, Velocity® and Leva® brand names.  The expandable technologies can be utilized in posterior, anterior and lateral surgical approaches.  To complement the expandable spacers, Spine Wave offers a comprehensive line of pedicle screws for both minimally invasive and traditional open approaches. Additionally, Spine Wave recently launched the Proficient® Posterior Cervical Spine System which is being very well received due to the high degree of angulation offered by its unique screw design.  The company is expanding rapidly and continues to recruit sales managers and independent distributors to fuel growth.  For more information on Spine Wave and its products, please visit

Terry Brennan, Chief Financial Officer
(203) 712-1810


January 23, 2018 OrthoSpineNews

WASHINGTONJan. 23, 2018 /PRNewswire-USNewswire/ — Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA) has announced its role in the successful granting of the first orthopedic de novo by the U.S. Food and Drug Administration (FDA) on December 19, 2017, enabling IlluminOss Medical, Inc. to initiate commercialization in the U.S. of the Bone Stabilization System for treatment of impending and actual pathological fractures of the humerus, radius and ulna from metastatic bone disease.

IlluminOss Medical retained MCRA in August of 2016 to lead interactions and correspondence with the FDA for the Bone Stabilization System. The IlluminOss System is a PET balloon infused with a photodynamic monomer, which when exposed to light, polymerizes the monomer, resulting in a solid intramedullary (IM) rod. This is an important treatment option for the fixation and stabilization of actual and impending pathological fractures of the humerus through a minimally invasive procedure. IlluminOss Medical’s Founder & Chief Technical Officer, Robert Rabiner said “Being granted the first orthopedic de novo by the FDA is a significant achievement for both IlluminOss Medical and our partner, MCRA. We knew messaging and presentation of data was critical to the success of our submission, and we knew MCRA had an incredible track record of positive FDA interactions, regulatory strategies, and success. After our successful U.S. clinical trial, MCRA was able to effectively present our clinical and performance data to the FDA in a clear concise manner. Their interactions minimized the potential miscommunications with the agency, and delivered the first Ortho de novo.”

Dave McGurl, Director of Regulatory Affairs, at MCRA, said “We are pleased that FDA has implemented the de novo pathway which allows innovative technologies, such as those being developed by IlluminOss Medical, find a pathway to U.S. market and ultimately to patients. MCRA is at the forefront of helping companies navigate this relatively new regulatory pathway, and achieve success in bringing novel devices to the U.S. market that was not possible even a few years ago.”

About Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA)
Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA) is the leading adviser and clinical research organization to the neuro-musculoskeletal and orthopedic industry. MCRA’s value lies in its industry experience and integration of five business value creators: regulatory, reimbursement, clinical research, healthcare compliance, and quality assurance. MCRA’s integrated approach of these key value creating initiatives, as well as orthopedic specialization, provides unparalleled expertise for its clients. MCRA has offices in Washington, DCManchester, CT, and New York, NY, and serves nearly 450 clients globally. MCRA has a demonstrated history of driving successful de novo and other regulatory submissions in all areas of the medical device industry including spine, orthopedics, cardio-vascular, diagnostic imaging, endoscopy, ophthalmics, general/plastic surgery, drug delivery, wound care, diabetes, dental, general healthcare, nephrology, neurology, cardiology, and in vitro diagnostic (IVD) devices.


David W. Lown
General Manager
212.583.0250 ext. 2111

SOURCE Musculoskeletal Clinical Regulatory Advisers, LLC


January 23, 2018 OrthoSpineNews

LEESBURG, Va., Jan. 23, 2018 (GLOBE NEWSWIRE) — K2M Group Holdings, Inc. (NASDAQ:KTWO) (the “Company” or “K2M”), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance™, today announced that fourth quarter and fiscal year 2017 financial results will be released after the market close on February 28th.

Management will host a conference call at 5:00 p.m. Eastern Time on February 28th to discuss the results of the fourth quarter and fiscal year 2017, and to host a question and answer session. Those who would like to participate may dial 844-579-6824 (734-385-2616 for international callers) and provide access code 3754359 approximately 10 minutes prior to the start of the call. A live webcast of the call will also be provided on the investor relations section of the Company’s website at

For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 3754359. The webcast will be archived on the investor relations section of the Company’s website.

About K2M

K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, developed, and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS®, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal, and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company’s technologies, techniques and leadership in the 3D-printing of spinal devices, enable K2M to compete favorably in the global spinal surgery market. For more information, visit and connect with us on FacebookTwitterInstagramLinkedIn and YouTube.

Forward-Looking Statements

Certain statements made in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are based on management’s expectations, estimates, projections, and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Additional information regarding these factors is contained in the sections entitled “Risk Factors” and “Management Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, as such factors are updated from time to time in our periodic filings with the SEC, each of which is accessible on the SEC’s website.

Investor Contact:
Westwicke Partners on behalf of K2M Group Holdings, Inc.Mike Piccinino, CFA, 443-213-0500

Source: K2M Group Holdings, Inc.


This article appears in: News Headlines

Referenced Stocks: KTWO


January 23, 2018 OrthoSpineNews

MELVILLE, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today announced the appointment of Adam Bergstein as Senior Vice President, Planning and Business Development. In this capacity, Mr. Bergstein will be responsible for strategic planning, business development, capital market activities and related endeavors.

From 2008 until 2017, Mr. Bergstein founded and operated PharmaShield, an analytics company that created the first known data model that accurately predicts litigation loss and the timing of outcomes in branded pharmaceutical patent cases. From 2006 through 2008, Mr. Bergstein worked as a consultant to a health economics group inside RAND Corporation, during which time he created derivatives to help mitigate risk within the broader healthcare markets. From 1998 through 2006, Mr. Bergstein was a private equity investor in the healthcare and technology sectors.

Mr. Bergstein has an MBA from the J.L. Kellogg Graduate School of Management with concentrations in finance and organizational behavior, as well as a Bachelor of Arts degree in Economics with distinction from the University of Pennsylvania.

“Based on the 33 human patients that received the precursor to BRTX-100, I believe that BioRestorative’s disc therapy stands an excellent chance of receiving regulatory clearance from the FDA within a relatively short time frame.  I believe the therapy will significantly improve the lives of so many with chronic lumbar disc disease,” Mr. Bergstein commented.

Mark Weinreb, CEO of BioRestorative, further commented, “We are extremely excited to have Adam join BioRestorative at this important time of our development. With his industry expertise, capital markets experience and impressive track record, Adam will be a strong addition to our senior management team as we accelerate our clinical, regulatory and business development activities.”

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ( develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.  Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells.  In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.  We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs.

• Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company’s Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.



January 19, 2018 OrthoSpineNews

JACKSON, Mich.Jan. 19, 2018 /PRNewswire/ — Henry Ford Allegiance Health is the first in Michigan to offer patients the advantages of the ExcelciusGPSTM surgical system. Innovative designs like the ExcelciusGPS are revolutionizing minimally invasive spine surgery and optimizing patient care by combining the benefits of navigation and robotics into one technology. This technology is designed to increase safety for patients and accuracy for their surgeons.

“Robot-assisted surgery is a new, emerging area that will become the standard in care,” said Henry Ford Allegiance Health neurosurgeon Frank La Marca, MD. “At Henry Ford Allegiance Health, we are committed to providing the highest quality of care for our spine surgery patients. We are excited to offer our patients the advantages of the Excelcius system, which allows us to perform minimally invasive procedures which may result in less blood loss, less muscle damage and a potentially faster recovery.”

One of the advantages of the ExcelciusGPS system is the inclusion of a GPS 3-D guidance system, designed to improve accuracy and optimize patient care by combining robotics with navigation, much like the GPS in a car. This advanced technology allows a neurosurgeon to place screws and implants in a very precise fashion while seeing exactly where to place their instruments in real-time.

Henry Ford Allegiance neurosurgeon Azam Basheer, MD, said, “The GPS navigation gives me continuous feedback and allows me to see everything in real time. Now, my colleagues and I can preprogram coordinates, so the robotic arm can assist in guiding us to precise locations in the patient’s spine. The result is safer, faster surgery with less radiation exposure and less need to reposition my patient.”

“Another advantage of ExcelciusGPS is that it allows us to make even safer, more consistent and smaller incisions,” said Henry Ford Allegiance neurosurgeon Armitraj Loganathan, MD. “This is valuable because it promotes healing and lessens scarring.”

About Henry Ford Allegiance Health
Henry Ford Allegiance Health (HFAH) is a 475-bed health system in Jackson, Michigan. HFAH complements traditional acute care services with mission-based services to support patient care across the continuum at every stage of life. With its Level II Trauma Center, Henry Ford Allegiance Health provides comprehensive care for severely injured patients. As a teaching hospital, Henry Ford Allegiance Health continually looks to the future with its Center for Health Innovation & Education and Graduate Medical Education program. Through its Health Improvement Organization (HIO), HFAH is also a national leader in forming community partnerships that innovatively address regional wellness and prevention needs. Visit to learn more.

About Henry Ford Health System
Henry Ford Health System (HFHS) is a six hospital system headquartered in Detroit, Michigan. HFHS is one of the nation’s leading comprehensive, integrated health systems, recognized for clinical excellence and innovation. It provides health insurance and health care delivery, including acute, specialty, primary and preventive care services backed by excellence in research and education. HFHS is a 2011 Malcolm Baldrige National Quality Award recipient. Visit to learn more.

SOURCE Henry Ford Allegiance Health

PHOTO: Henry Ford Allegiance Health neurosurgeons Azam Basheer, MD, (left) and Amritraj Loganathan, MD, with the ExcelciusGPS robot

Related Links


January 19, 2018 OrthoSpineNews

NAPLES, Fla.Jan. 19, 2018 /PRNewswire/ — Catalyst OrthoScience, Inc. has been granted four new patents by the United States Patent and Trademark Office for technologies incorporated in the CSR™ Total Shoulder Replacement System.  The Catalyst CSR™ Total Shoulder System is a new canal-sparing, anatomic shoulder arthroplasty system that provides consistently reproducible shoulder joint restoration with an humeral implant that is smaller, more anatomically-shaped, and less invasive than traditional shoulder replacement surgery.

U.S. Patent Number


Patent Issue Date


Glenoid Arthroplasty with Multi-directional Fixation

November 14, 2017


Humeral Arthroplasty

November 14, 2017


Glenoid Arthroplasty with Offset Reamers

November 14, 2017


Glenoid Arthroplasty

October 3, 2107

These patents expand the portfolio of Catalyst intellectual property related to the Company’s proprietary glenoid and humeral implant designs and instrumentation. “The granting of these patents endorses the extent of our technology and provides Catalyst with further protection for its product offerings in the shoulder replacement market,” said Bob Kaufman, CEO of Catalyst OrthoScience. “We have built a solid intellectual property portfolio and will continue to work to extend the depth and breadth of that protection.”

With core technology driven by surgeon and patient need, Catalyst has been able to draw a loyal following of orthopedic surgeons since receiving FDA clearance for the CSR™ total shoulder replacement solution last year. “Catalyst’s core technology is truly innovative, as evidenced by not only the growing patent portfolio, but also by the growing number of high caliber shoulder specialists who have embraced Catalyst as an important part of their clinical offering,” said Rod Allen, Catalyst’s Senior Vice President of Sales and Marketing.

Catalyst OrthoScience was founded in 2014 by orthopedic surgeon Steven Goldberg, M.D. who realized, based on his own experience as a fellowship-trained shoulder specialist, that improvements were needed to make shoulder replacement surgery less invasive and to give patients a more normal feeling shoulder after surgery.  “It feels great to be granted these patents,” said Dr. Goldberg. “I’m still amazed at how much our team has accomplished in such a short timeframe, and now patients are seeing the benefit.”

About Catalyst OrthoScience Inc.

Headquartered in Naples, FL, Catalyst OrthoScience develops and markets innovative medical device solutions that make orthopedic surgery less invasive and more efficient for both surgeons and patients.

The company’s first offering is the Catalyst CSR Shoulder System. The Catalyst CSR is a single-tray total shoulder arthroplasty system containing a non-spherical humeral implant for consistent anatomic joint line restoration and specialized glenoid instrumentation for a less invasive approach that preserves the natural anatomy and removes less of the patient’s bone.

Catalyst OrthoScience’s products are marketed under a portfolio of brands including Catalyst OrthoScience® and Catalyst CSR™. For additional information on the Company, please visit

SOURCE Catalyst OrthoScience, Inc.

Related Links


January 19, 2018 OrthoSpineNews

PHILADELPHIAJan. 19, 2018 /PRNewswire/ — Joint replacement surgery carries the risk of developing an infection in the replaced joint, which can lead to a so-called revision or re-do of the joint replacement. However, current diagnostic practices can fail to detect bacteria in 30-50 percent of clinical cases, complicating or delaying appropriate treatment. Thomas Jefferson University researchers have found that genomic analysis using next generation sequencing (NGS), can identify infecting organisms in over 80 percent of cases of infected joint replacement that had previously escaped detection. The research was published January 17th 2018 in the Journal of Bone and Joint Surgery.

“This method can help detect pathogens that we would otherwise miss using standard approaches, namely culture,” said senior author Javad Parvizi, MD, Vice Chairman of Research and Professor of Orthopedic Surgery at the Rothman Institute at Thomas Jefferson University. “The study has revealed unexpected pathogens and let us to select more appropriate and effective treatments for patients.”

In order to test the ability to isolate infective organisms, Dr. Parvizi and colleagues prospectively enrolled patients undergoing a revision joint replacement over a 9-month period in 2016, and assessed for organisms identified using traditional method: culture, side by side with NGS.

The results showed that NGS identified organisms in 89 percent of infected cases versus 61 percent with culture. Furthermore, NGS was able to detect the pathogen in 81 percent of the cases that were negative for pathogens by the standard culture method, and which would have been missed otherwise.

One patient, whose case was described in a separate paper in Arthroplasty Today, reported to the emergency department with an infected joint replacement. Although standard culture was unable to identify the pathogen, NGS diagnostic tests resulted in an unexpected finding: The infection was caused by Streptococcus canis, an organism found in dogs. Further questioning of the patient confirmed that he had been scratched by his dog a few days prior to the joint infection. Once the pathogen was known, the patient could be switched to more effective antibiotics and recovered well.

“The fact that we can use this technology to detect organisms in culture-negative patients with an infected prosthesis may be significant, and could help us provide targeted treatment for these patients,” said co-author Karan Goswami, MD, a research fellow and PhD candidate affiliated with the Rothman Institute at Jefferson. “However, further study is required to validate our findings in larger numbers and determine the significance of NGS signal on treatment outcomes. A multicenter trial is underway to explore this question.”

The American Academy of Microbiologists (AAM) recently published a report supporting the use of NGS, stating, “…NGS has the potential to dramatically revolutionize the clinical microbiological laboratory by replacing current time-consuming techniques with a single all-inclusive diagnostic test.”

“Because of its promising role in diagnosing patients with periprosthetic joint infection, we have already begun to use the genomic test at our institution to isolate organisms in patients with suspected joint infection. NGS has provided critical information for the management of cases of periprosthetic joint infection at our institution, and we work closely with our microbiology colleagues to optimize treatment for these patients” said Dr. Parvizi.

Dr. Parvizi has ownership interest in MicroGenDX, the laboratory that provided next generation sequencing of samples in this study. No other disclosures were reported.

Article references:
M Tarabichi, et al., “Diagnosis of Periprosthetic Joint Infection: The Potential of Next-Generation Sequencing” the Journal of Bone and Joint Surgery, DOI: 10.2106/JBJS.17.00434 , 2018.

M Tarabichi, et al., “Diagnosis of Streptococcus canis periprosthetic joint infection: the utility of next-generation sequencing,” Arthroplasty Today, DOI:  10.1016/j.artd.2017.08.005 2017.

SOURCE Thomas Jefferson University Hospital

Related Links


January 18, 2018 OrthoSpineNews

January 16, 2018

HUNTLEY, Ill.–(BUSINESS WIRE)–Centric Medical, a division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology, announced today announced today that the U.S. Food and Drug Administration (FDA) has given 510(k) marketing clearance to the Cannulated Screw Internal Fixation System. This clearance further expands the offering of Cannulated Screws for Centric Medical, to be used in Foot & Ankle reconstruction procedures.

“I am excited to add another cannulated screw option to our rapidly growing foot and ankle portfolio. This addition has allowed for a more robust offering for distal extremity procedures including reconstruction, joint fusion, osteotomies, fracture repair, arthrodesis and fracture fixation,” said Mariusz Knap, Vice President of Marketing and Business Development for Life Spine. “The system is extremely easy to use, low profile and offers partially and fully threaded options. I am incredibly proud that Centric Medical saw five 510K clearances in 2017 and I think a full cannulated screw selection is an integral step to a complete foot and ankle portfolio.”

The Cannulated Screw Internal Fixation System is a streamlined multi-component system comprised of titanium alloy, with a wide variety of diameters and lengths. The new options, which are specifically indicated for the forefoot, come in 2.0, 2.5, and 3.0mm diameters with headed and headless designs. This system complements the previously FDA cleared range of 3.5-7.5mm diameters indicated for the midfoot and hindfoot which also offer designs with and without a head.

About Centric Medical

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Centric Medical, which is privately held, is based in Huntley, Illinois. For more information, please visit:


Centric Medical
Mr. Omar Faruqi
Chief Financial Officer


January 18, 2018 OrthoSpineNews

WARSAW, Ind.Jan. 18, 2018 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter and full-year sales and earnings conference call will be broadcast over the Internet on Tuesday, January 30, 2018, at 8 a.m. Eastern Time.  A news release detailing the quarterly and full-year results will be made available at 7 a.m. Eastern Time the morning of the conference call.

The audio webcast can be accessed via Zimmer Biomet’s Investor Relations website at It will be archived for replay following the conference call.

Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (888) 312-9837 and entering conference ID 7278985.  For a complete listing of international toll-free and local numbers, please visit  A digital recording will be available 24 hours after the completion of the conference call, from January 31, 2018 to March 1, 2018.  To access the recording, U.S. callers should dial (888) 203-1112 and international callers should dial +1 (719) 457-0820, and enter the Access Code ID 7278985.

About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit, or follow Zimmer Biomet on Twitter at

SOURCE Zimmer Biomet Holdings, Inc.

Related Links